Morphine News and Research

Latest Morphine News and Research

QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today it has completed patient enrolment for a pivotal Phase 3 registration trial (Study 009) for MoxDuo IR. The comparative study was designed to evaluate analgesic efficacy and safety of MoxDuo IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone, for managing moderate to severe pain in patients who have undergone total knee replacement surgery.

5 Dec 2010

Exposure to nicotine during pregnancy may cause learning disabilities in children: Research

Exposure to nicotine during pregnancy leads to a decrease in adult stem cells and a change in synaptic plasticity in the hippocampus of the offspring, according to new research from the University of Alabama at Birmingham presented at Neuroscience 2010, the annual Society for Neuroscience meeting in San Diego in November.

4 Dec 2010

New study finds no decrease in patient harm at hospitals

Despite concerted efforts, no decreases in patient harm were detected at 10 randomly selected North Carolina hospitals between 2002 and 2007, according to a new study from the Stanford University School of Medicine, Harvard Medical School and the Institute for Healthcare Improvement.

25 Nov 2010

Ziconotide could promote suicidal tendencies in vulnerable patients: Research

24 Nov 2010

Ziconotide could promote suicidal tendencies: Study

The active agent ziconotide, the synthetic toxin of the cone snail (Conus magus), was acclaimed a safe alternative to morphine when it was introduced six years ago. Now it is increasingly suspected of causing patients to commit suicide. Researchers working under the auspices of Prof. Christoph Maier (Director of the Pain Clinic Bergmannsheil at the Ruhr University in Bochum) presume that ziconotide not only suppresses the transmission of pain stimuli, but also deteriorates the frame of mind and could simultaneously reduce anxiety and impulse control.

23 Nov 2010

New findings help identify impact of prenatal environment on early parental care on brain

New findings released today help identify the long-term impact of the prenatal environment and early parental care on the brain. Using animals as models, researchers help explain why early inflammation and a mother's exposure to drugs such as nicotine and high doses of pain killers have lasting consequences for children and even future generations.

16 Nov 2010

New noninvasive technique provides low-level electrical stimulation to reduce pain

A simple, noninvasive technique providing low-level electrical stimulation of the brain produces significant pain-reducing effects in humans, reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

4 Nov 2010

Single injection of morphine to fight persistent pain reduces testosterone level: Research

A single injection of morphine to fight persistent pain in male rats is able to strongly reduce the hormone testosterone in the brain and plasma, according to a new paper published in Molecular Pain.

4 Nov 2010

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Cadence Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

3 Nov 2010

Nitric oxide inhalation reduces pain in sickle cell disease patients

Inhaling nitric oxide appears to safely and effectively reduce pain crises in adults with sickle cell disease, researchers report.

20 Oct 2010

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

Nektar Therapeutics today presented new preclinical data demonstrating that NKTR-181, a mu-opioid analgesic with a novel molecular structure, dramatically reduces abuse liability while providing analgesia comparable to oxycodone and morphine.

18 Oct 2010

FDA approves Vivitrol for treatment of opioid-dependent patients

The U.S. Food and Drug Administration today approved Vivitrol to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

13 Oct 2010

Abiraterone Phase III clinical data to be presented at ESMO meeting

Attendees at next week's European Society of Medical Oncology (ESMO) meeting in Milan will be presented with top-line Phase III Clinical Trials data on Abiraterone in the treatment of castration-resistant prostate cancer.

8 Oct 2010

Semi-synthetic opioid may improve withdrawal symptoms in infants

Thousands of infants each year have exposure to opioids before they are born. Over half of these infants are born with withdrawal symptoms severe enough to require opioid replacement treatment in the nursery. Such treatment is associated with long hospital stays which interferes with maternal/infant bonding. Now, a team of researchers at Thomas Jefferson University has tested a semi-synthetic opioid they say has the potential to improve the treatment of these newborns, which could save hundreds of millions in healthcare costs annually if future tests continue to show benefit.

7 Oct 2010

Repinotan blocks respiratory depressant effects of morphine without altering pain-relieving effects

A new drug called repinotan blocks the respiratory depressant effects of morphine-like opioid drugs—without altering their potent pain-relieving effects, according to a study in the October issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

6 Oct 2010

QRxPharma's A$14 million Placement oversubscribed

QRxPharma Limited has today announced a Placement which raised A$14 million and which was significantly oversubscribed.

1 Oct 2010

L'Albufera Natural Park's irrigation channels contain cocaine, ecstasy

The water in the canals and irrigation channels in the L'Albufera Natural Park in Valencia contain cocaine, ecstasy and a further six drugs. This has been confirmed by a study carried out by researchers from the University of Valencia (UV), who have issued a warning about the continued presence of these substances on wildlife and human health.

24 Sep 2010

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI).

24 Sep 2010

Kim Hames says case was not euthanasia

Western Australia has been debating euthanasia for a while and in a new development, Health Minister and Deputy Premier Kim Hames has admitted that as a GP he administered the painkiller morphine to hasten a cancer patient's death. He said in his statement that what he had done was legal and not euthanasia – which he opposed. His reasoning was that the pain relieving medication was intended to ease a patient's suffering rather than end their life.

23 Sep 2010

PNNL, 59th Medical Wing collaborate to improve drug tests for illicit usage

A new collaboration between the Department of Energy's Pacific Northwest National Laboratory and the Air Force's 59th Medical Wing hopes to improve on drug tests for illicit drug use and abuse. Not only are the researchers looking for a better indicator of current or past use, but they'd like to be able to identify people prone to abusing drugs in the first place.

18 Sep 2010

Morphine News and Research

Latest Morphine News and Research

QRxPharma completes patient enrolment of pivotal MoxDuo IR phase 3 study

Exposure to nicotine during pregnancy may cause learning disabilities in children: Research

New study finds no decrease in patient harm at hospitals

Ziconotide could promote suicidal tendencies in vulnerable patients: Research

Ziconotide could promote suicidal tendencies: Study

New findings help identify impact of prenatal environment on early parental care on brain

New noninvasive technique provides low-level electrical stimulation to reduce pain

Single injection of morphine to fight persistent pain reduces testosterone level: Research

FDA grants Cadence marketing approval for OFIRMEV injection in management of pain and fever

Nitric oxide inhalation reduces pain in sickle cell disease patients

Nektar presents NKTR-181 preclinical data at ASA 2010 Annual Meeting

FDA approves Vivitrol for treatment of opioid-dependent patients

Abiraterone Phase III clinical data to be presented at ESMO meeting

Semi-synthetic opioid may improve withdrawal symptoms in infants

Repinotan blocks respiratory depressant effects of morphine without altering pain-relieving effects

QRxPharma's A$14 million Placement oversubscribed

L'Albufera Natural Park's irrigation channels contain cocaine, ecstasy

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Kim Hames says case was not euthanasia

PNNL, 59th Medical Wing collaborate to improve drug tests for illicit usage

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Morphine News and Research

Latest Morphine News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in